[go: up one dir, main page]

MX2012004548A - Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. - Google Patents

Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.

Info

Publication number
MX2012004548A
MX2012004548A MX2012004548A MX2012004548A MX2012004548A MX 2012004548 A MX2012004548 A MX 2012004548A MX 2012004548 A MX2012004548 A MX 2012004548A MX 2012004548 A MX2012004548 A MX 2012004548A MX 2012004548 A MX2012004548 A MX 2012004548A
Authority
MX
Mexico
Prior art keywords
preventing
nervous system
central nervous
degenerative disorders
novel compositions
Prior art date
Application number
MX2012004548A
Other languages
English (en)
Other versions
MX340807B (es
Inventor
Gary Lee
Robert Boyd
Philip Rybczynski
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2012004548A publication Critical patent/MX2012004548A/es
Publication of MX340807B publication Critical patent/MX340807B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos, así como también composiciones y métodos que los usan para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Parkinson.
MX2012004548A 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. MX340807B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19
PCT/US2010/051447 WO2011049736A1 (en) 2009-10-19 2010-10-05 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
MX2012004548A true MX2012004548A (es) 2012-07-04
MX340807B MX340807B (es) 2016-07-27

Family

ID=43879775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Country Status (26)

Country Link
US (4) US8604206B2 (es)
EP (2) EP3143875B1 (es)
JP (2) JP5805649B2 (es)
KR (3) KR101880411B1 (es)
CN (2) CN105367485B (es)
AR (1) AR078606A1 (es)
AU (3) AU2010308396B2 (es)
BR (1) BR112012009121A2 (es)
CA (1) CA2778348C (es)
CY (1) CY1118966T1 (es)
DK (1) DK2490532T3 (es)
ES (2) ES2814178T3 (es)
HR (1) HRP20170236T1 (es)
HU (1) HUE033116T2 (es)
IL (1) IL219160B (es)
LT (1) LT2490532T (es)
MX (2) MX340807B (es)
PL (1) PL2490532T3 (es)
PT (1) PT2490532T (es)
RS (1) RS55679B1 (es)
RU (2) RU2015147509A (es)
SG (1) SG10201507159XA (es)
SI (1) SI2490532T1 (es)
SM (2) SMT201700105T1 (es)
TW (1) TWI642434B (es)
WO (1) WO2011049736A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170236T1 (hr) * 2009-10-19 2017-04-07 Amicus Therapeutics, Inc. Novi pripravci za sprječavanje i/ili liječenje degenerativnih poremećaja središnjeg živčanog sustava
CN102647905B (zh) 2009-10-19 2015-09-09 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的新颖组合物
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
ES2924829T3 (es) * 2012-03-27 2022-10-11 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
CN110573492A (zh) 2017-04-25 2019-12-13 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020223310A2 (en) * 2019-04-29 2020-11-05 Thomas Jefferson University Methods for treating neurodegenerative disorders
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
BR112023022567A2 (pt) * 2021-04-30 2024-02-06 Vanqua Bio Inc Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos
EP4658726A1 (en) * 2023-01-31 2025-12-10 Bioeutectics Corporation Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
ATE243196T1 (de) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
MXPA06007378A (es) 2003-12-23 2007-01-26 Musc Found For Res Dev Metodos y composiciones para la prevencion y tratamiento de enfermedades o condiciones inflamatorias.
EP1860101B1 (en) 2006-05-24 2011-04-06 Amicus Therapeutics, Inc. Tartrate sale of isofagomine and methods of use
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
WO2007150064A2 (en) * 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
JP2010525084A (ja) 2007-04-26 2010-07-22 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2505243T3 (es) * 2009-04-09 2014-10-09 Amicus Therapeutics, Inc. Agentes terapéuticos para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
HRP20170236T1 (hr) 2009-10-19 2017-04-07 Amicus Therapeutics, Inc. Novi pripravci za sprječavanje i/ili liječenje degenerativnih poremećaja središnjeg živčanog sustava
EP2957295B1 (en) * 2009-10-19 2017-08-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
CN102647905B (zh) 2009-10-19 2015-09-09 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的新颖组合物
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
JP6258245B2 (ja) 2018-01-10
ES2617192T3 (es) 2017-06-15
AU2016203817A1 (en) 2016-06-30
SMT201700105B (it) 2017-03-08
US20160326114A1 (en) 2016-11-10
PL2490532T3 (pl) 2017-05-31
AU2010308396B2 (en) 2016-04-28
CY1118966T1 (el) 2018-01-10
CA2778348C (en) 2022-08-23
AU2016203817B2 (en) 2017-09-07
ES2814178T3 (es) 2021-03-26
JP2013508366A (ja) 2013-03-07
PT2490532T (pt) 2017-02-23
IL219160B (en) 2018-12-31
US20180273474A1 (en) 2018-09-27
DK2490532T3 (en) 2017-02-27
AR078606A1 (es) 2011-11-23
WO2011049736A1 (en) 2011-04-28
JP2015157822A (ja) 2015-09-03
TW201116279A (en) 2011-05-16
KR101769396B1 (ko) 2017-08-18
CN105367485B (zh) 2018-04-17
RU2015147509A (ru) 2019-01-14
CN102655747A (zh) 2012-09-05
TWI642434B (zh) 2018-12-01
RU2581058C2 (ru) 2016-04-10
KR20170096220A (ko) 2017-08-23
US20110092541A1 (en) 2011-04-21
KR20120104549A (ko) 2012-09-21
SG10201507159XA (en) 2015-10-29
HRP20170236T1 (hr) 2017-04-07
JP5805649B2 (ja) 2015-11-04
HUE033116T2 (en) 2017-11-28
EP3143875B1 (en) 2020-05-27
LT2490532T (lt) 2017-03-27
AU2010308396A1 (en) 2012-05-03
RS55679B1 (sr) 2017-07-31
RU2012120759A (ru) 2013-11-27
CA2778348A1 (en) 2011-04-28
CN105367485A (zh) 2016-03-02
SMT201700105T1 (it) 2017-03-08
KR101813988B1 (ko) 2018-01-02
BR112012009121A2 (pt) 2017-08-29
US10421724B2 (en) 2019-09-24
HK1219724A1 (zh) 2017-04-13
EP2490532A4 (en) 2013-06-12
IL219160A0 (en) 2012-06-28
EP3143875A1 (en) 2017-03-22
KR101880411B1 (ko) 2018-07-19
SI2490532T1 (sl) 2017-03-31
EP2490532B1 (en) 2016-11-23
AU2017272296A1 (en) 2018-01-25
US9409862B2 (en) 2016-08-09
MX368459B (es) 2019-10-03
EP2490532A1 (en) 2012-08-29
US8604206B2 (en) 2013-12-10
AU2017272296B2 (en) 2019-07-11
KR20180001588A (ko) 2018-01-04
MX340807B (es) 2016-07-27
US20140080871A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SG179120A1 (en) Novel compounds
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY161415A (en) A homeopathic formulation
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2010007392A (es) Antagonistas de trpa1.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010007391A (es) Antagonistas de trpa1.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
TW200642690A (en) Composition for treating central nervous system disorders
WO2009151618A3 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration